Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

669
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
669
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.5K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.5K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

605
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
605
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

576
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
576

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-reported harassment during Japanese surgical residency: secondary analysis of a nationwide survey of newly board-certified surgeons.

Surgery today·2026
Same author

Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.

Annals of surgical oncology·2026
Same author

Breast Desmoid-Type Fibromatosis Mimicking Carcinoma on Imaging: A Case Report.

Surgical case reports·2026
Same author

Timing and motivation behind the decision to become a surgeon: Gender and optimal recruitment insights.

Surgery today·2026
Same author

Revisiting nuclear grade as a high-risk marker for predicting upgrade in ductal carcinoma in situ.

Human pathology·2026
Same author

Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing.

Breast cancer (Tokyo, Japan)·2026

Related Experiment Video

Updated: Feb 3, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K

Arthralgia in 329 Patients Taking Aromatase Inhibitors.

Yoshiya Horimoto1, Mitsue Saito1, Fujio Kasumi1

  • 1Department of Breast Oncology, Juntendo University School of Medicine, Tokyo, Japan.

Breast Care (Basel, Switzerland)
|November 7, 2018
PubMed
Summary

Arthralgia, a common side effect of aromatase inhibitors, affects 27% of post-menopausal women. Switching to a selective estrogen receptor modulator (SERM) often resolves these joint pain symptoms.

Keywords:
Aromatase inhibitorArthralgiaBreast cancer

More Related Videos

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

7.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 3, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

7.0K
Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
09:11

Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors

Published on: November 23, 2019

7.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Arthralgia is a frequent adverse event in post-menopausal women undergoing treatment with aromatase inhibitors.
  • The exact mechanism driving aromatase inhibitor-induced arthralgia is not yet fully understood.

Purpose of the Study:

  • To determine the incidence and severity of arthralgia in patients using aromatase inhibitors.
  • To explore potential factors associated with arthralgia in this patient population.

Main Methods:

  • Retrospective analysis of medical records from outpatients prescribed aromatase inhibitors.
  • Evaluation of treatment changes and symptom resolution following medication adjustments.

Main Results:

  • Arthralgia was reported by 27% of 329 patients on aromatase inhibitors (anastrozole or exemestane).
  • Arthralgia was a significant reason for treatment modification, leading 16% of patients to switch or discontinue therapy.
  • Symptom resolution was frequently observed after switching to a selective estrogen receptor modulator (SERM).
  • Lower arthralgia rates were noted in patients with prior endocrine therapy, but no correlation with chemotherapy or bone density was found.

Conclusions:

  • Selective estrogen receptor modulator (SERM) therapy in combination with aromatase inhibitors may offer a practical clinical approach to manage arthralgia.
  • Further research into the mechanisms and management of aromatase inhibitor-induced arthralgia is warranted.